NEW YORK, July 4 (Reuters) - Wuxi Biologics (2269.HK), a Chinese company that makes ingredients for AstraZeneca's COVID-19 vaccine, may be a step closer to being taken off a U.S. trade list that it landed on five months ago, wiping HK$77 billion($9.9 billion) off its market value.
Chinese authorities allowed a U.S. export control officer to conduct inspections of at least one company in the city of Wuxi last week, a U.S. Commerce Department official said.
路透纽约 7 月 4 日电---无锡生物制品( 2269 . HK )是一家为阿斯利康 2019 冠状病毒病疫苗生产原料的中国公司,五个月前被列入美国贸易名单,市值蒸发 770 亿港元(合 99 亿美元)。
美国商务部一位官员说,中国当局上周允许一名美国出口管制官员对无锡市的至少一家公司进行检查。
CXO回来了